Harbin Gloria Pharmaceuticals - Asset Resilience Ratio

Latest as of September 2025: 12.90%

Harbin Gloria Pharmaceuticals (002437) has an Asset Resilience Ratio of 12.90% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Harbin Gloria Pharmaceuticals carry for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥390.82 Million

≈ $57.19 Million USD Cash + Short-term Investments

Total Assets

CN¥3.03 Billion

≈ $443.38 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2024)

This chart shows how Harbin Gloria Pharmaceuticals's Asset Resilience Ratio has changed over time. See 002437 net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Harbin Gloria Pharmaceuticals's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Harbin Gloria Pharmaceuticals.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥390.82 Million	12.9%
Total Liquid Assets	CN¥390.82 Million	12.90%

Asset Resilience Insights

Moderate Liquidity: Harbin Gloria Pharmaceuticals has 12.90% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Harbin Gloria Pharmaceuticals Industry Peers by Asset Resilience Ratio

Compare Harbin Gloria Pharmaceuticals's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Changchun High & New Technology Industries Group Inc SHE:000661	Drug Manufacturers - Specialty & Generic	3.73%
Yuhan Corp. KO:000100	Drug Manufacturers - Specialty & Generic	0.99%
Tasly Pharmaceutical Group Co Ltd SHG:600535	Drug Manufacturers - Specialty & Generic	9.09%
Zhejiang Hisun Pharmaceutical Co Ltd SHG:600267	Drug Manufacturers - Specialty & Generic	0.02%
Zhejiang Jiuzhou Pharm Co Ltd SHG:603456	Drug Manufacturers - Specialty & Generic	0.01%
Shanghai Yizhong Pharmaceutical Co Ltd SHG:688091	Drug Manufacturers - Specialty & Generic	26.36%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%
Cronos Group Inc TO:CRON	Drug Manufacturers - Specialty & Generic	69.94%

Annual Asset Resilience Ratio for Harbin Gloria Pharmaceuticals (2012–2024)

The table below shows the annual Asset Resilience Ratio data for Harbin Gloria Pharmaceuticals.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	1.06%	CN¥30.00 Million ≈ $4.39 Million	CN¥2.83 Billion ≈ $413.40 Million	-0.18pp
2022-12-31	1.24%	CN¥50.56 Million ≈ $7.40 Million	CN¥4.07 Billion ≈ $596.18 Million	-7.93pp
2013-12-31	9.17%	CN¥270.00 Million ≈ $39.51 Million	CN¥2.94 Billion ≈ $430.65 Million	+6.05pp
2012-12-31	3.12%	CN¥80.00 Million ≈ $11.71 Million	CN¥2.56 Billion ≈ $375.28 Million	--

pp = percentage points

About Harbin Gloria Pharmaceuticals

SHE:002437 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.15 Billion

CN¥7.86 Billion CNY

Market Cap Rank

#8518 Global

#2214 in China

Share Price

CN¥3.52

Change (1 day)

-2.76%

52-Week Range

CN¥2.44 - CN¥4.04

All Time High

CN¥11.06